{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:38:29Z","timestamp":1790289509738,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Clinics of North America"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.suc.2024.10.007","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T04:24:29Z","timestamp":1736223869000},"page":"435-454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Medical Management of Ulcerative Colitis and Crohn\u2019s Disease\u2014Strategies for Inducing and Maintaining Remission"],"prefix":"10.1016","volume":"105","author":[{"given":"Mohamed","family":"Tausif Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhytha","family":"Kasiraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliha","family":"Naseer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.suc.2024.10.007_bib1","article-title":"Aminosalicylates for induction of remission or response in Crohn's disease","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/ibd.20099","article-title":"5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review","volume":"13","author":"Gisbert","year":"2007","journal-title":"Inflamm Bowel Dis"},{"issue":"36","key":"10.1016\/j.suc.2024.10.007_bib3","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.3748\/wjg.v23.i36.6628","article-title":"Glucocorticosteroid therapy in inflammatory bowel diseases: from clinical practice to molecular biology","volume":"23","author":"Dubois-Camacho","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.suc.2024.10.007_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/CEG.S208020","article-title":"Novel therapeutic options for people with ulcerative colitis: an update on recent developments with janus kinase (JAK) inhibitors","volume":"13","author":"Troncone","year":"2020","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.suc.2024.10.007_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/CEG.S4512","article-title":"The impact of biologics on health-related quality of life in patients with inflammatory bowel disease","volume":"2","author":"Vogelaar","year":"2009","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.suc.2024.10.007_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211059954","article-title":"Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues","volume":"14","author":"Peyrin-Biroulet","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"issue":"8","key":"10.1016\/j.suc.2024.10.007_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"issue":"17","key":"10.1016\/j.suc.2024.10.007_bib8","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","article-title":"Anti-integrin therapy for inflammatory bowel disease","volume":"24","author":"Park","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.suc.2024.10.007_bib9","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"3","key":"10.1016\/j.suc.2024.10.007_bib10","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"48","key":"10.1016\/j.suc.2024.10.007_bib11","doi-asserted-by":"crossref","first-page":"6888","DOI":"10.3748\/wjg.v28.i48.6888","article-title":"Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease","volume":"28","author":"Xu","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"13","key":"10.1016\/j.suc.2024.10.007_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cells12131730","article-title":"Novel small molecules in IBD: current state and future perspectives","volume":"12","author":"Jefremow","year":"2023","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib13","first-page":"265","article-title":"Sphingosine-1 phosphate receptor modulators: the next wave of oral therapies in inflammatory bowel disease","volume":"18","author":"Choden","year":"2022","journal-title":"Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.suc.2024.10.007_bib14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/apt.15097","article-title":"Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease","volume":"49","author":"Shivaji","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.suc.2024.10.007_bib15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.12659\/MSM.890331","article-title":"A\u00a0guide to prepare patients with inflammatory bowel diseases for anti-TNF-alpha therapy","volume":"20","author":"Chebli","year":"2014","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.suc.2024.10.007_bib16","first-page":"11","article-title":"Use of thiopurines in inflammatory bowel disease: an update","volume":"20","author":"Singh","year":"2022","journal-title":"Int Res"},{"issue":"4","key":"10.1016\/j.suc.2024.10.007_bib17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4103\/sjg.sjg_496_21","article-title":"Methotrexate in inflammatory bowel disease: a primer for gastroenterologists","volume":"28","author":"AlAmeel","year":"2022","journal-title":"Saudi J Gastroenterol"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib18","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","article-title":"AGA technical review on the management of moderate to severe ulcerative colitis","volume":"158","author":"Singh","year":"2020","journal-title":"Gastroenterology"},{"issue":"26","key":"10.1016\/j.suc.2024.10.007_bib19","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.suc.2024.10.007_bib20","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1097\/MIB.0000000000000130","article-title":"Role in calcineurin inhibitors for inflammatory bowel disease in the biologics era: when and how to use","volume":"20","author":"Nakase","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.suc.2024.10.007_bib21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ecco-jcc\/jju016","article-title":"Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies","volume":"9","author":"Dias","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"issue":"3","key":"10.1016\/j.suc.2024.10.007_bib22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1053\/j.gastro.2018.12.009","article-title":"AGA clinical practice guidelines on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Ko","year":"2019","journal-title":"Gastroenterology"},{"issue":"26","key":"10.1016\/j.suc.2024.10.007_bib23","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"4947","key":"10.1016\/j.suc.2024.10.007_bib24","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"issue":"3","key":"10.1016\/j.suc.2024.10.007_bib25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1053\/j.gastro.2018.12.008","article-title":"AGA technical review on the management of mild-to-moderate ulcerative colitis","volume":"156","author":"Singh","year":"2019","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.suc.2024.10.007_bib26","first-page":"2031","article-title":"Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews","volume":"19","author":"Feagan","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib27","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","volume":"2016","author":"Timmer","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.suc.2024.10.007_bib28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.suc.2024.10.007_bib29","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.crohns.2008.05.011","article-title":"Management of loss of response to anti-TNF drugs: change the dose or change the drug?","volume":"2","author":"Van Assche","year":"2008","journal-title":"J\u00a0Crohns Colitis"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib30","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/ibd\/izy313","article-title":"A\u00a0practical guide to the safety and monitoring of new IBD therapies","volume":"25","author":"Click","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib31","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/ibd\/izad120","article-title":"Safety and monitoring of inflammatory bowel disease advanced therapies","volume":"30","author":"Bhat","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.suc.2024.10.007_bib32","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S1542-3565(05)00980-8","article-title":"Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease","volume":"4","author":"Takeuchi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.suc.2024.10.007_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/gut.2007.128231","article-title":"Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease","volume":"57","author":"Ananthakrishnan","year":"2008","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.suc.2024.10.007_bib34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1258\/shorts.2011.011007","article-title":"Pubic rami and sacral insufficiency fractures resulting in osteomyelitis, vulval abscess, discharging bone fragments and pelvic instability","volume":"2","author":"Johnstone","year":"2011","journal-title":"JRSM Short Rep"},{"issue":"8","key":"10.1016\/j.suc.2024.10.007_bib35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/ueg2.12442","article-title":"Review article: updated management of acute severe ulcerative colitis: from steroids to novel medical strategies","volume":"11","author":"Calmejane","year":"2023","journal-title":"United European Gastroenterol J"},{"issue":"2","key":"10.1016\/j.suc.2024.10.007_bib36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ecco-jcc\/jjab177","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: surgical treatment","volume":"16","author":"Spinelli","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib37","article-title":"Antibiotics for the induction and maintenance of remission in ulcerative colitis","volume":"5","author":"Gordon","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib38","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.suc.2024.10.007_bib39","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.cgh.2019.09.040","article-title":"Perioperative and postoperative management of patients with crohn's disease and ulcerative colitis","volume":"18","author":"Barnes","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.suc.2024.10.007_bib40","article-title":"Managing ulcerative colitis after surgery","volume":"9","author":"Calvino-Suarez","year":"2022","journal-title":"Front Med"},{"issue":"9","key":"10.1016\/j.suc.2024.10.007_bib41","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/17474124.2020.1807325","article-title":"Endoscopy after surgery in inflammatory bowel disease: crohn's disease recurrence and pouch surveillance","volume":"14","author":"Vespa","year":"2020","journal-title":"Expet Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.suc.2024.10.007_bib42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","article-title":"Development of a crohn's disease activity index. National cooperative Crohn's disease study","volume":"70","author":"Best","year":"1976","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.suc.2024.10.007_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ecco-jcc\/jjz187","article-title":"ECCO guidelines on therapeutics in crohn's disease: surgical treatment","volume":"14","author":"Adamina","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"issue":"4","key":"10.1016\/j.suc.2024.10.007_bib44","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.suc.2024.10.007_bib45","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on therapeutics in Crohn's Disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J\u00a0Crohns Colitis"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib46","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1097\/MIB.0000000000001158","article-title":"Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in crohn's disease: a bayesian network meta-analysis: republished","volume":"23","author":"Coward","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib47","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1542-3565(04)00122-3","article-title":"Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.suc.2024.10.007_bib48","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ajg.2011.71","article-title":"Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.suc.2024.10.007_bib49","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/ibd\/izaa127","article-title":"Trends of 5-aminosalicylate medication use in patients with crohn disease","volume":"27","author":"Noureldin","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.suc.2024.10.007_bib50","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2014.10.011","article-title":"Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis","volume":"148","author":"Hazlewood","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.suc.2024.10.007_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11894-023-00863-y","article-title":"Mild Crohn's disease: definition and management","volume":"25","author":"Claytor","year":"2023","journal-title":"Curr Gastroenterol Rep"},{"issue":"15","key":"10.1016\/j.suc.2024.10.007_bib52","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib53","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.suc.2024.10.007_bib54","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.suc.2024.10.007_bib55","first-page":"2203","article-title":"Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial","volume":"92","author":"Oren","year":"1997","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.suc.2024.10.007_bib56","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2036.2012.05002.x","article-title":"Review article: the natural history of postoperative Crohn's disease recurrence","volume":"35","author":"Buisson","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"14","key":"10.1016\/j.suc.2024.10.007_bib57","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM197510022931403","article-title":"Reoperation and recurrence in Crohn's colitis and ileocolitis; Crude and cumulative rates","volume":"293","author":"Greenstein","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.suc.2024.10.007_bib58","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/ajg.2014.297","article-title":"Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies","volume":"109","author":"Frolkis","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.suc.2024.10.007_bib59","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00384-008-0542-9","article-title":"The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies","volume":"23","author":"Reese","year":"2008","journal-title":"Int J Colorectal Dis"},{"issue":"1","key":"10.1016\/j.suc.2024.10.007_bib60","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00000658-200001000-00006","article-title":"Risk factors for surgery and postoperative recurrence in Crohn's disease","volume":"231","author":"Bernell","year":"2000","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.suc.2024.10.007_bib61","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.gastro.2016.10.039","article-title":"American gastroenterological association institute technical review on the management of Crohn's disease after surgical resection","volume":"152","author":"Regueiro","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.suc.2024.10.007_bib62","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/ecco-jcc\/jjy216","article-title":"Systematic review and network meta-analysis of medical therapies to prevent recurrence of post-operative Crohn's Disease","volume":"13","author":"Burr","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"issue":"12","key":"10.1016\/j.suc.2024.10.007_bib63","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3748\/wjg.v26.i12.1231","article-title":"Venous thromboembolism in inflammatory bowel disease","volume":"26","author":"Cheng","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"8","key":"10.1016\/j.suc.2024.10.007_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/nu15081991","article-title":"Nutritional status and its detection in patients with inflammatory Bowel Diseases","volume":"15","author":"Jablonska","year":"2023","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.suc.2024.10.007_bib65","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.clnu.2016.12.027","article-title":"ESPEN guideline: clinical nutrition in inflammatory bowel disease","volume":"36","author":"Forbes","year":"2017","journal-title":"Clin Nutr"},{"issue":"2","key":"10.1016\/j.suc.2024.10.007_bib66","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ncp.10608","article-title":"Nutrition management of the high-output fistulae","volume":"36","author":"Couper","year":"2021","journal-title":"Nutr Clin Pract"},{"issue":"5","key":"10.1016\/j.suc.2024.10.007_bib67","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/jpen.2647","article-title":"Association between tunneled catheter placement and catheter-associated deep venous thrombosis in adults with inflammatory bowel disease receiving home parenteral nutrition: a retrospective cohort study","volume":"48","author":"Siddiqui","year":"2024","journal-title":"JPEN - J Parenter Enter Nutr"},{"key":"10.1016\/j.suc.2024.10.007_bib68","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7890161","article-title":"Perioperative care of patients with inflammatory bowel disease: focus on nutritional support","volume":"2018","author":"Stoner","year":"2018","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.suc.2024.10.007_bib69","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.2147\/JIR.S300989","article-title":"The immunomodulatory functions of butyrate","volume":"14","author":"Siddiqui","year":"2021","journal-title":"J\u00a0Inflamm Res"},{"issue":"1","key":"10.1016\/j.suc.2024.10.007_bib70","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1038\/s41467-022-31171-0","article-title":"Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery","volume":"13","author":"Zhou","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.suc.2024.10.007_bib71","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11938-021-00364-9","article-title":"Health maintenance for adult patients with inflammatory Bowel Disease","volume":"19","author":"Hashash","year":"2021","journal-title":"Curr Treat Options Gastroenterol"}],"container-title":["Surgical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610924001543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039610924001543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T20:38:46Z","timestamp":1751402326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039610924001543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0039610924001543"],"URL":"https:\/\/doi.org\/10.1016\/j.suc.2024.10.007","relation":{},"ISSN":["0039-6109"],"issn-type":[{"value":"0039-6109","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Management of Ulcerative Colitis and Crohn\u2019s Disease\u2014Strategies for Inducing and Maintaining Remission","name":"articletitle","label":"Article Title"},{"value":"Surgical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suc.2024.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}